Using blood and tumor data to predict cancer treatment response
Part of Cancer, Lungs & breathing clinical trials.
This study looks at “multiomics” information (many types of biological data, like blood and lab markers) to predict how well cancer treatments may work for you. It may help doctors choose better treatments in the future based on what your body is doing during therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign informed consent before any study tests begin
- Be 18 years or older
- Be well enough to do daily activities (rated ECOG 0 to 2)
- Do not have another active cancer that needed treatment within the last 2 years
- Be able to understand the study and participate (no severe mental impairment)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study follows how cancer responds to standard (usual) treatment by using blood samples and de-identified health data. It may help researchers understand whether “liquid biopsy” blood testing can reflect how well therapy is working.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.